Binimetinib
Targeted induction before immunotherapy shows limited benefit in advanced melanoma
CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.
FDA approves Braftovi-Mektovi combination for lung cancer
The FDA approved encorafenib plus binimetinib for treatment of certain patients with non-small cell lung cancer.
Sequencing trial shows ‘interesting trend’ with ‘sandwich’ approach to melanoma treatment
A “sandwich” approach to melanoma treatment consisting of immunotherapy between two targeted therapy courses showed a trend toward improved total PFS, according to study results presented at ESMO Virtual Congress 2020.
FDA approves Braftovi with Erbitux for metastatic colorectal cancer subset
The FDA approved encorafenib in combination with cetuximab for adults with previously treated BRAF V600E-mutant metastatic colorectal cancer.
Encorafenib regimens confer quality-of-life, survival benefit in BRAF V600E-mutant metastatic colorectal cancer
A combination of encorafenib and cetuximab, with or without binimetinib, demonstrated significant improvement in patient-reported quality-of-life assessments compared with standard-of-care chemotherapy among patients with BRAF V600E-mutant metastatic colorectal cancer, according to results of the randomized phase 3 BEACON CRC study scheduled for presentation at Gastrointestinal Cancers Symposium.